Ornithine Phenylacetate

Phase 2Small molecule

OOcera Therapeutics

Ornithine Phenylacetate is one of 85 small molecule programs targeting Acute Liver Failure. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Liver FailureActive, not recruiting

EncephalopathyActive, not recruiting

CirrhosisActive, not recruiting

Acute Liver FailurePhase 2

Active, not recruiting

EncephalopathyPhase 2

Active, not recruiting

CirrhosisPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

252 competitors in Cirrhosis

#DrugCompanyPhaseTrials

Crestor

AstraZeneca

Preclinical

2 2

Farxiga

AstraZeneca

Preclinical

1 3

Thalomid

Bristol-Myers Squibb

Preclinical

1 4

Revia

Teva

Preclinical

1 5

Cipro

Bayer

Preclinical

1 6

Dobutrex

Eli Lilly

Preclinical

1 7

Azulfidine

Pfizer

Preclinical

1 8

HEPCLUDEX

Gilead

Preclinical

1 9

Ornithine Phenylacetate

OOcera Therapeutics

Phase 2

1 10

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute Liver Failure1 trial

Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury

Completed·WWilliam Lee·Phase 2·NCT01548690·47 enrolled

Encephalopathy1 trial

Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)

Completed·OOcera Therapeutics·Phase 2·NCT01966419·231 enrolled

Cirrhosis1 trial

Effects of the Administration of Ornithine Phenylacetate in Patients With Cirrhosis and Upper Gastrointestinal Bleeding

Completed·HHospital Universitari Vall d'Hebron Research Institute·Phase 2/3·NCT01434108·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Ornithine Phenylacetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ornithine Phenylacetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ornithine Phenylacetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ocera Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: OOcera Therapeutics

Ornithine Phenylacetate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute Liver Failure1 trial

Encephalopathy1 trial

Cirrhosis1 trial

References

Drug Info

Quick Facts

Related News